Apologies if this has been posted before. Just got an email from...

Apologies if this has been posted before. Just got an email from Orthocell, touting the fact that Veritas Securities Limited have started covering OCC, with a $0.90 price target no less:

https://mcusercontent.com/418010b734f74e4d79ccacb45/files/f36818c1-6b34-8cb8-bbe2-38a0f2a6c03b/OCC_180423.pdf

Jeez, its like I wrote the thing!:

"➢ Regenerative medicine pioneers: Orthocell’s founders, Paul Anderson CEO and Professor Ming Hao Zheng CSO previously commercialized a cell
therapy for cartilage repair (MACI) in Australia which now underpins the US$1.5bn valuation of Vericel (VCEL-NASDAQ). Orthocell is their next venture"

"The advanced stage of Orthocell’s products and the recent acquisition of competitors increases the likelihood of it being an M&A target." particularly that one of Bio HOrizons previous main rivals (demerged) Zimmer Biomet announced an offer of US$275m for Embody and its early stage Tapestry product (an electro spun membrane).

" Possible takeover target? The acquisition playbook for orthopaedic device companies involves buying devices which solve an unmet clinical need with strong clinical data, FDA clearance and revenue. Orthocell should meet these requirements when it receives FDA clearance for Remplir which we expect to occur in late FY24."

The bit many of you will want to read:

"The BioHorizons licencing deal and the strong evidence for the efficacy of Remplir gives us line of sight on $18m revenue by FY26."